Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan

References

1. Hiroi S, Morikawa S, Motomura K, Mori H. Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan Figshare 2023 [View Article]
   [Google Scholar]
2. Ministry of Health, Labour and Welfare of Japan Novel coronavirus (COVID-19) situation report; 2022 https://www.mhlw.go.jp/stf/covid19/kokunainohasseijoukyou_00006.html accessed 4 June 2022
3. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 2020; 182:812–827 [View Article]
   [Google Scholar]
4. Tanaka H, Hirayama A, Nagai H, Shirai C, Takahashi Y et al. Increased transmissibility of the SARS-CoV-2 alpha variant in a Japanese population. Int J Environ Res Public Health 2021; 18:7752 [View Article]
   [Google Scholar]
5. Earnest R, Uddin R, Matluk N, Renzette N, Turbett SE et al. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Cell Rep Med 2022; 3:100583 [View Article]
   [Google Scholar]
6. Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol 2022; 94:2376–2383 [View Article] [PubMed]
   [Google Scholar]
7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020; 383:2603–2615 [View Article]
   [Google Scholar]
8. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med 2022; 386:494–496 [View Article]
   [Google Scholar]
9. Prime minister of Japan and His Cabinet Novel coronavirus vaccines total number of vaccine doses administered to date; 2022 accessed 4 June 2022
10. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 2022; 3:e52–e61 [View Article]
    [Google Scholar]
11. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020; 117:7001–7003 [View Article] [PubMed]
    [Google Scholar]
12. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021; 595:572–577 [View Article] [PubMed]
    [Google Scholar]
13. Hiroi S, Morikawa S, Motomura K, Mori H. Neutralization titres Figshare 2022 https://figshare.com
    [Google Scholar]
14. Yu J, Collier A-RY, Rowe M, Mardas F, Ventura JD et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med 2022; 386:1579–1580 [View Article] [PubMed]
    [Google Scholar]
15. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021; 596:276–280 [View Article] [PubMed]
    [Google Scholar]
16. Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ et al. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. iScience 2021; 24:103341 [View Article] [PubMed]
    [Google Scholar]
17. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. Lancet Infect Dis 2022; 22:766–767 [View Article]
    [Google Scholar]
18. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the omicron variant: a systematic review. J Med Virol 2022; 94:2969–2976 [View Article]
    [Google Scholar]
19. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med 2021; 27:2136–2143 [View Article] [PubMed]
    [Google Scholar]
20. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 2022; 399:1303–1312 [View Article] [PubMed]
    [Google Scholar]
21. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021; 374:abm0829 [View Article] [PubMed]
    [Google Scholar]
22. Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 2022; 603:493–496 [View Article] [PubMed]
    [Google Scholar]
23. Terpos E, Trougakos IP, Apostolakou F, Charitaki I, Sklirou AD et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol 2021; 96:E257–E259 [View Article]
    [Google Scholar]
24. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E et al. Plasma neutralization of the SARS-CoV-2 omicron variant. N Engl J Med 2022; 386:599–601 [View Article]
    [Google Scholar]
25. Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S et al. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci Immunol 2022; 7:eabn8590 [View Article]
    [Google Scholar]
26. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022; 386:1532–1546 [View Article]
    [Google Scholar]